A systematic analysis of the evidence finds that approximately half of all approved drugs either have no meaningful benefit over placebo or carry risks that outweigh their benefits. This is not a fringe view — it is the conclusion of leading medical researchers and former journal editors.

The Evidence

Marcia Angell, former editor-in-chief of the New England Journal of Medicine, reviewed the evidence and concluded: "It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines."

Richard Smith, former editor of the British Medical Journal, wrote: "Most of what appears in peer-reviewed journals is scientifically weak."

John Ioannidis, professor of medicine at Stanford, published a landmark 2005 paper demonstrating that most published research findings are false, due to small sample sizes, multiple testing, and publication bias.

"Most of what appears in peer-reviewed journals is scientifically weak." — Richard Smith, former editor of the British Medical Journal

The Cochrane Collaboration's Findings

The Cochrane Collaboration — the gold standard for independent systematic reviews — has found that many widely used drugs have little or no evidence of benefit:

  • Antidepressants: Benefit over placebo is clinically insignificant for mild-to-moderate depression
  • Statins: Primary prevention benefit is marginal; absolute risk reduction is very small
  • Proton pump inhibitors: Long-term use causes vitamin B12 deficiency, magnesium deficiency, and increased fracture risk
  • Bisphosphonates: Reduce fracture risk modestly but cause osteonecrosis of the jaw and atypical femur fractures

The Approval Standard Problem

The FDA approves drugs based on two clinical trials showing superiority to placebo. This standard does not require:

  • Comparison to existing treatments
  • Long-term safety data
  • Clinically meaningful effect sizes
  • Independent verification of trial data

A drug can be approved if it shows a statistically significant but clinically meaningless improvement over placebo in two trials — even if it is inferior to existing treatments and has serious long-term risks.

The Implication

Patients and physicians should approach drug therapy with healthy skepticism. For most conditions, the evidence for drug therapy is weaker than commonly believed, and the risks are greater. Non-pharmacological interventions — diet, exercise, sleep, stress reduction — are often more effective and always safer.